Your browser doesn't support javascript.
loading
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.
Rijnders, Maud; Robbrecht, Debbie G J; Oostvogels, Astrid A M; van Brakel, Mandy; Boormans, Joost L; Aarts, Maureen J B; Balcioglu, Hayri E; Hamberg, Paul; Voortman, Jens; Westgeest, Hans M; Lolkema, Martijn P; de Wit, Ronald; van der Veldt, Astrid A M; Debets, Reno.
Affiliation
  • Rijnders M; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. m.rijnders@erasmusmc.nl.
  • Robbrecht DGJ; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Oostvogels AAM; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • van Brakel M; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Boormans JL; Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Aarts MJB; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Balcioglu HE; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam, Rotterdam, The Netherlands.
  • Voortman J; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Westgeest HM; Department of Medical Oncology, Amphia Hospital Breda, Breda, The Netherlands.
  • Lolkema MP; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • de Wit R; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • van der Veldt AAM; Departments of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Debets R; Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Cancer Immunol Immunother ; 72(3): 759-767, 2023 Mar.
Article in En | MEDLINE | ID: mdl-35976415
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Transitional Cell / Antibodies, Monoclonal, Humanized Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2023 Type: Article Affiliation country: Netherlands
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Transitional Cell / Antibodies, Monoclonal, Humanized Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2023 Type: Article Affiliation country: Netherlands